NCCN Foundation Awards Grants to Five Young Investigators
The NCCN Foundation has awarded its sixth series of Young Investigator Awards to five oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.  FORT WASHINGTON, PA — The NCCN Foundation® has awarded grants to five young investigators from NCCN Member Institutions. These awardees, who are dedicated to advancing and discovering n... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - April 2, 2016 Category: Cancer & Oncology Source Type: news

Four Researchers Awarded Grants to Investigate Effectiveness of Nintedanib* in Lung, Colorectal, and Gastrointestinal Cancers
The NCCN ORP has awarded four research grants to investigate the effectiveness of nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib* (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal can... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 24, 2014 Category: Cancer & Oncology Source Type: news

NCCN Foundation
The NCCN Foundation® has awarded the fourth series of Young Investigator Awards to five young investigators from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care. FORT WASHINGTON, PA – The NCCN Foundation®, which, through private philanthropy, empowers people through knowledge and advances the mission of the National Comprehensive Cancer Netwo... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - May 29, 2014 Category: Cancer & Oncology Source Type: news

NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Volasertib* in Hematologic Malignancies
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of volasertib in hematologic malignancies. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the safety and clinical effectiveness... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - May 22, 2014 Category: Cancer & Oncology Source Type: news

Pharmacia Gives $3.15 Million Grant to NCCN to Advance Innovative Cancer Research Collaboration
-- NCCN to study clinical applications of therapies in treatment of breast, gynecological, and other forms of cancer -- [PEAPACK, NJ] – Pharmacia Corporation today announced it has provided a $3.15 million grant to the National Comprehensive Cancer Network (NCCN) for the development and review of clinical oncology research protocols and trials in breast, gynecological and other forms of cancer. The grant will provide funding for clinical research to identify treatment advances that improve p... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 15, 2013 Category: Cancer & Oncology Source Type: news

NCCN Qualifies Lehigh Valley Health Network for Affiliate Research Project
The NCCN Oncology Research Program has qualified Lehigh Valley Health Network, Lehigh Valley, PA, as the latest addition to its Affiliate Research Project. Lehigh Valley Health Network is a community-based affiliate of Moffitt Cancer Center—one of the 23 NCCN Member Institutions. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Affiliate Research Project (ARP), developed by the NCCN Oncology Research Program (ORP), has qualified Le... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 11, 2013 Category: Cancer & Oncology Source Type: news

Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
The NCCN Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib as a result of funding through the AVEO/Astellas collaboration. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These gr... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 15, 2012 Category: Cancer & Oncology Source Type: news

Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate and define clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced mela... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 6, 2012 Category: Cancer & Oncology Source Type: news

NCCN Qualifies First Community Sites for Affiliate Research Project
The NCCN Oncology Research Program (ORP) has qualified seven sites from Fox Chase Cancer Center, Seattle Cancer Care Alliance, and University of Alabama at Birmingham as part of its Affiliate Research Project (ARP). The ARP is dedicated to improving patient outcomes and advancing clinical research through collaboration with NCCN, NCCN Member Institutions, and community-based affiliate networks. FORT WASHINGTON, PA – The NCCN Affiliate Research Project (ARP), developed by the NCCN ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - July 10, 2012 Category: Cancer & Oncology Source Type: news

NCCN Collaborates with AVEO and Astellas on Innovative Cancer Research
NCCN recently received a research grant from AVEO Pharmaceuticals and Astellas Pharma, Inc. to evaluate the role of tivozanib in the treatment of solid tumors. Tivozanib is a potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that it has e... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - February 16, 2012 Category: Cancer & Oncology Source Type: news

NCCN Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim to Investigate Afatinib in Solid Tumors
NCCN recently received a $2 million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to gain further insight into the use of the investigational compound Afatinib (BIBW 2992) in solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pha... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 10, 2011 Category: Cancer & Oncology Source Type: news

NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline
NCCN recently received $4 million in the form of two research grants from GlaxoSmithKline to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor, both promising therapies in the treatment of advanced melanoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarde... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 11, 2011 Category: Cancer & Oncology Source Type: news

Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
The NCCN Oncology Research Program received $4 million in research funding from GlaxoSmithKline to support research at NCCN Member Institutions in order to evaluate the effectiveness of ofatumumab (Arzerra®, GlaxoSmithKline) in hematologic malignancies and pazopanib (Votrient™, GlaxoSmithKline) in the treatment of solid tumors. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - August 31, 2011 Category: Cancer & Oncology Source Type: news

Researchers Receive Grants from NCCN Oncology Research Program Funded Through Pfizer
The NCCN Oncology Research Program received $2.1 million in research funding from Pfizer, Inc. to support research at NCCN Member Institutions in order to gain further insight into the use of axitinib in various tumor types. FORT WASHINGTON, PA — The National Comprehensive Cancer Network®`s (NCCN®`s) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Axitinib Request f... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - July 5, 2011 Category: Cancer & Oncology Source Type: news

NCCN Advances Oncology Imaging Research through the NCCN Specialized Imaging Research Consortium
NCCN has established the NCCN Specialized Imaging Research Consortium, a new initiative of the NCCN Oncology Research Program, to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies. FORT WASHINGTON, PA — Imaging plays an important role in clinical cancer care, and the increasing availability and use of advanced imaging methods have created a need for expertise in such techniques in order to guide their appropria... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - May 27, 2011 Category: Cancer & Oncology Source Type: news

NCCN Receives $2.1 Million in Oncology Research Funding from Pfizer
NCCN recently received a $2.1 million research grant from Pfizer to gain further insights into the use of the investigational compound Axitinib in various tumor types. Investigators from NCCN Member Institutions are eligible to apply for the research funding. November 30, 2010 FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clin... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 30, 2010 Category: Cancer & Oncology Source Type: news

NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline
NCCN recently received two individual $2 million research grants from GlaxoSmithKline to evaluate the effectiveness of ofatumumab in hematologic malignancies and pazopanib in the treatment of solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. July 27, 2010 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical stud... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - July 27, 2010 Category: Cancer & Oncology Source Type: news

NCCN Survey Analyzes Clinical Trial Accrual at Academic Cancer Centers
Identifying clinical trial benchmarking metrics and best practices at NCCN Member Institutions is the focus of a recent survey conducted by the National Comprehensive Cancer Network® (NCCN®). A poster presentation of the survey analysis will be featured at the 2010 ASCO Annual Meeting on June 7, 2010. June 4, 2010 FORT WASHINGTON — Clinical research is at the heart of National Comprehensive Cancer Network® (NCCN®) center operations, as it constitut... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - June 4, 2010 Category: Cancer & Oncology Source Type: news

NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. November 10, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 10, 2009 Category: Cancer & Oncology Source Type: news

NCCN Holds Oncology Research Best Practices Conference
NCCN is holding the NCCN Oncology Research Best Practices Conference™, an interactive forum to discuss the regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made. Scheduled for October 26 – 27 in Bethesda, MD, the conference will include lectures, interactive workshops, and panel discussions on topics that challenge the conduct of oncology research as well as topics related to ethical consideration... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 14, 2009 Category: Cancer & Oncology Source Type: news

NCCN Oncology Research Program Celebrates 10th Anniversary by Closing in on $20 Million in Funding; Program Expands into Developmental Therapies
The NCCN Oncology Research Program (ORP) nears the $20 million mark in total funding and enhances its current model to include funding for therapeutics in development as well as those already FDA-approved. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers (NCCN Member Institutions) in order to advance therapeutic options for patients with cancer. April 29, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCC... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - April 29, 2009 Category: Cancer & Oncology Source Type: news

NCCN Receives $4 Million Oncology Research Grant from Wyeth
NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding. January 15, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - January 15, 2009 Category: Cancer & Oncology Source Type: news

Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN
NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - December 1, 2008 Category: Cancer & Oncology Source Type: news

NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
NCCN has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center is the coordinating center for the study. November 24, 2008 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 24, 2008 Category: Cancer & Oncology Source Type: news

NCCN Receives Major Grant for Anti-Cancer Drug Study
JENKINTOWN, Pa., November 15, 2007 — The National Comprehensive Cancer Network (NCCN), ImClone Systems Incorporated and Bristol-Myers Squibb have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in head and neck cancer using cetuximab. Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania is the coordinating center for this study, with Corey Langer, M.D., serving as Project Chairman. Cetuximab, also known by its brand name ERBITUX®, is current... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 15, 2007 Category: Cancer & Oncology Source Type: news

NCCN Receives $2 Million Grant from Pfizer
Funding will support innovative cancer research JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) and Pfizer, Inc., have entered into a collaboration to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors. Sutent is being studied in a broad range of solid tumors. “NCCN’s goal is to improve the quality, effectiveness and efficiency of oncology prac... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 5, 2006 Category: Cancer & Oncology Source Type: news

NCCN and Roche Collaborate on Innovative Cancer Research
JENKINTOWN, Pa., October 31, 2005 — The National Comprehensive Cancer Network (NCCN) announced that it has entered into a collaboration with Roche Laboratories, Inc. to develop and review ongoing oncology research protocols and trials examining Xeloda® (capecitabine) in combination with radiologic therapy, and other drugs and biologics in the treatment of solid tumors including esophageal, gastric and pancreatic cancers. “NCCN’s mission is to improve cancer care by studying and evaluating new ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 31, 2005 Category: Cancer & Oncology Source Type: news

Diane E. Paul, MS, RN, Joins National Comprehensive Cancer Network as Vice President, Clinical Trials Network
JENKINTOWN, Pa., June 13, 2005 — William T. McGivney, Ph.D., CEO of the National Comprehensive Cancer Network (NCCN), announces that Diane E. Paul, MS, RN, has joined NCCN as Vice President, Clinical Trials Network. In this role, Paul will be responsible for developing a centralized, standardized infrastructure for the conduct of clinical trials among NCCN’s 19 member institutions. “This network will be of interest to pharmaceutical/biotechnology companies for the conduct of their trials. And... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - June 13, 2005 Category: Cancer & Oncology Source Type: news

Researchers Receive $1,886,237 in Funding from NCCN Clinical Trials Network
ROCKLEDGE, PA, February 20, 2003 - The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, is very pleased to announce the awarding of $1,886,237 in research grants provided through the NCCN Clinical Trials Network (CTN). “NCCN’s Clinical Trials Network, a program devoted to facilitating the development of promising new therapeutics to improve patient outcomes, is very pleased to offer research funding to support investigator-initiated... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - February 20, 2003 Category: Cancer & Oncology Source Type: news

The National Comprehensive Cancer Network Provides Physicians Easier Identification of Clinical Trials for Their Patients
ROCKLEDGE, PA, November 5, 2002 – The National Comprehensive Cancer Network (NCCN) today announced changes made to their Web site (www.nccn.org) which will allow physicians to more easily locate clinical trials. Physicians seeking new treatments for their patients with cancer often turn to clinical trials for answers. These research studies include trials testing new treatments, such as a new cancer drug or a new combination of drugs, new approaches to surgery or radiation therapy, or new ther... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 5, 2002 Category: Cancer & Oncology Source Type: news

The National Comprehensive Cancer Network Launches Clinical Trials Network to Speed Drug Discovery
Nineteen of the world`s leading cancer centers align to advance cancer treatment ROCKLEDGE, PA, June 5, 2002 - The National Comprehensive Cancer Network (NCCN) announces the launch of its Clinical Trials Network (CTN), a new strategy for advancing cancer therapies through clinical trials to improve patient care. A national, centralized infrastructure, CTN facilitates the initiation of clinical trials by ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - June 5, 2002 Category: Cancer & Oncology Source Type: news